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but at a cost of increasedacuteischemiccomplications,notably
non-Qwavemyocardialinfarction,Themechanismforthisexcess
riskis unknown.
Methods.Of 2,038 high risk patientsundergoingcoronary
interventionin the EPICtrial,directionalatherectomywasper-
formedin 197 (10%).Patientsrandomlyreceivedthe chimeric
glycoproteinIIb/HIaantibody7E3(c7E3),as a bolusor a bolus
and 12-hinfusionor placebo.Studyend pointsincludeddeath,
myocardialinfarction,repeatinterventionor bypasssurgery.
Sincedirectionalatherectomywasapprovedbythe Foodand
Drug Administrationin 1990,its use has expandedin the






















lowerbaselinerisk for acute complicationsbut had a higher
incidenceofanymyocardialinfarction(10.7%vs.6.3%,p = 0.021)
andnon-Qwavemyocardialinfarction(9.6Y0vs.4.9%,p = 0.006).
Bolus and infusionof c7E3 reducednon-Qwave myocardial
infarctionsby71Y0afteratherectomy(15.470forplacebovs. 4.570




Conclusions.The EPICtrial confirmedthe increasedrisk of
non-Qwavemyocardialinfarctionwithdirectionalathereetomy
use comparedwith PTCA.A bolus and 12-h infusionof the
glycoproteinIIb/IIIareceptorinhibitorc7E3abolishedthisexcess




found to result in greater initial angiographicsuccess,a
reductionin angiographicrestenosisfor lesionslocatedin the





PTCA (1,2).When the resultsof the CoronaryAngioplasty
Versus ExcisionalAtherectomy Trial (CAVEAT)-I and
CAVEAT-IIare combined,adversein-hospitalevents(death,
clinicallydetectedmyocardialinfarction,emergencycoronary
bypasssurgeryor abruptclosure)occurredin 96(15%)of 661
patientsundergoingdirectionalatherectomycomparedwith53
(8%) of 656 undergoingPTCA. In particular,non-Q wave
myocardialinfarctionemergedas a majordrawbackof direc-
tional atherectomy,with a greater than twofoldincreasein
creatinekinasemyocardialisoenzymeband (CK-MB)eleva-
tionsfrom870with PTCAto 1870after directionalatherec-
tomy(1,2).















tion of IschemicComplications(EPIC) trial (4,5) demon-
strated that potent platelet antagonismwith the chimeric
glycoproteinIIb/HIa receptor antibody7E3 Fab (c7E3)re-
ducedacute ischemiccomplicationsafter high risk coronary
interventionby 3590.One hundredninety-sevenpatientsin




contributeto the etiologyof these events. We therefore
examinedthe effect of the glycoproteinHb/IIIa receptor
inhibitorc7E3on adverseoutcomesin thosepatientsunder-
goingdirectionalatherectomyin the EPIC trial.
Methods
EPICtrial designand patientpopulation. The EPIC trial
wasconductedin 56 sitesacrossthe UnitedStates(4,5).Two
thousandninety-ninepatientsundergoinghighriskangioplasty
were randomlyassignedin double-blindmannerto receivea
bolusof0.25mgkgbodyweightofchimeric7E3Fabor a bolus
followedby a 12-hinfusion(10 pgjmin)of c7E3or placebo.
Patientsconsideredat highriskfor vesselclosurewere those
whohad 1)acuteevolvingmyocardialinfarction;2)postinfarc-
tion or unstableangina;and 3) clinicalor angiographichar-
acteristicsindicatinghighriskaccordingto the modifiedcrite-
ria of the AmericanCollegeof Cardiologyand American
HeartAssociation(6).Patientswereexcludediftheywere>80
yearsor had a knownbleedingdiathesis,recentmajoropera-
tion or a stroke within the previous2 years. All patients
receivedaspirin and heparin before the intervention,and
intravenousheparinwascontinuedfor at least 12h after the
procedure.
EPIC trial end points. The primary,30-dayend pointof
the trial was a compositeof eventsthat compriseddeath,
myocardialinfarction,emergencycorona~ arterybypassgraft
surgeryor repeatemergencycoronaryangioplasty.Emergency
stentingfor abrupt closurewas includedas a surrogatefor
emergencybypasssurgery,andtheneedforintraaorticballoon
counterpulsationwasusedasa markerforsignificantrecurrent
ischemiain patientswho were not otherwisecandidatesfor
repeatintervention.Alladverseendpointsweredeterminedin
blindedmannerby an independentclinicaleventscommittee





wererequiredforthe diagnosisof infarctionin the subsequent
24 h: 1) an elevationof CK or its MBisozymeat least three
timestheupperlimitofnormal,whichwasalsoat leasta 33%
increasefrom the previous“valley”value (definedas a 25Y0
decreasefromthe previouspeakvaluebut remainingat least
twicetheupperlimitofnormal);or 2) an increasein CKor its
MBisozymeby at least 100%and remainingthree timesthe
upper limitof normalafter a 50Y0decreasefrom a previous
peak level.Myocardialinfarctionoccurringin the hospital
after24h wasdeterminedbythe developmentof newpatho-
logicQ wavesin at leasttwocontiguousleadsor an elevation
ofCKor itsMBisozymemorethanthreetimestheupperlimit
ofnormaland50$70greaterthanthepreviousvalleylevel.After
hospitaldischarge,either a new Q wave or a CK or MB




as major,minoror insignificantaccordingto Thrombolysisin
MyocardialInfarctioncriteria(7).Angiographicassessmentof
the target lesionsand proceduraland angiographicresults






variablesare summarizedas meanvalues,witht testsusedfor
testingfor distributiondifferencesbetweengroups.Medians
and the Wilcoxontest were used when it was expectedthat
distributionswouldbe nonnormal.The associationof non-Q
wavemyocardialinfarctionwithcovariateswasstudiedusing
logisticregression.Onlynon-Qwavemyocardialinfarctions
that were the first prima~ end point event to occurwere
includedin these analyses.Adjustmentfor treatmentgroup
effectswasperformedin all analysesbyincludingan indicator
variable for the bolus treatment group and an indicator
variable for the bolus plus infusiontreatment group, All
covariateswere studiedindividuallyand adjustedfor treat-
ment.For the regressionmodelfor predictorsof non-Qwave
myo ardialinfarction,a stepwiseprocedurewasusedto select
!covaiatesfromage,gender,atherectomyor angioplastypro-
cedure,graftor nativevesseltreated and unstableanginaat
enrollment;treatmentgroupwasforcedinto the model.Age
was the only candidatecontinuousvariablefor the model;
becauseriskwas expectedto increasewith age, analysisfor
nonlinearitywasnot incorporated.Onlytreatedpatientswere
included.After thismodelwasselected,interactionsbetween
treatmentand the selectedvariablewith the same stepwise











(n= 1,818) (n= 197) p Value
Men 1,306(72%) 157(80%) 0.019
Meanage(yr) 60 57 <0.001
Diabetesmellitus 458(25%) 35(18%) 0.023
Hypertension 985(54%) 102(52%) 0.547
Hypercholesterolemia 965(53%) 109(55%) 0.599
Currentsmoker 598(33%) 73(37%) 0.265
PreviousMI 697(38%) 63(32%) 0.089
Multivesseldisease 845(47%) 73(37%) 0.014
Unstableanginaat enrollment 429(24%) 51(26%) 0.482
Datapresentedare number(%) of patients.DCA= directionalcoronary




the 2,038patientswho receivedthe studyagentin the EPIC
trial, 197patients(10%)underwentdirectionalatherectomy
and 1,818patients(8794)had PTCAperformed.The remain-
der either receivedthe studyagent but did not undergoa
percutaneousintervention(n= 17)or hadrecordsthatdidnot
indicatethe typeofinterventionalprocedureperformed.Table
1 presentsthe baselinedemographiccharacteristicsfor the
PTCAanddirectionalatherectomypatientgroups.Therewere
significantdifferencesin the demographicprofilesof the two
groups,withdirectionalatherectomygrouppatientsappearing
to be a lowerrisk cohortoverall.Thesepatientswere more
oftenmale(80%vs.72~o,p = 0.019),had a lowerprevalence
of diabetesmellitus(1890vs.25Y0,p = 0.023)and were less
likelyto have multi-vesselcoronaryartery disease(47%vs.
37%,p = 0.014).
Table2 presentsthe lesionand proceduralcharacteristics
for the PTCAand directionalatherectomygroups.The direc-
tionalatherectomygrouprepresenteda cohortwithlowerrisk
lesions.Boththe left anteriordescendingcoronaryarteryand
bypassgrafts were more frequentlytreated by directional
atherectomythan PTCA.Directionalatherectomywasassoci-
atedwitha greaterreductionin diameterstenosis(p < 0.001),
a higherproportionof vesselswithnormalflowat the end of
the procedure (p = 0.008)and less major dissectionthan
PTCA(p = 0.023).However,the incidenceof distalemboli-
zation was doubledwith directionalatherectomy(4’%0for
directionalatherectomyvs.2% for PTCA,p = 0.015).
Thirty-dayoutcomes. Proceduralsuccess,definedas a re-
duction in lesion diameter stenosisto <50%, without in-
hospitaldeath due to proceduralcomplications,urgentstent
placementor urgentcoronarybypasssurgery,wasgreaterwith
directionalatherectomythanPTCA(188[95%]of 197patients
for directionalatherectomyvs. 1,663[92%]of 1,818patients
forPTCA,p = 0.055).Theincidenceofabruptclosurewaslow
and wassimilarin both groups(2.5Y0for directionalatherec-
tomyvs.3.0%for PTCA,p = 0.702).

































Death rateswerecomparablein the twogroups,but there
weredifferencesin the ratesof myocardialinfarction(Fig.1).
Although the total myocardialinfarction rate in patients
undergoingdirectionalatherectomywasgreater than that in
patientsundergoingPTCA(10.7%fordirectionalatherectomy
vs. 6.3?Z0for PTCA,p = 0.021),the occurrenceof Q wave
infarctionswassimilarin the twogroups.Themajordifference
in infarctionrateswasaccountedfor by an increasein non-Q
wavemyocardialinfarctionfrom4.9Y0in the patientsunder-
Figure1. Frequency of Q wave(left)andnon-Qwavemyocardial
infarction(right)at 30 days in patients undergoing PTCA or direc-

















Table3. MultivariableLogisticRegression Modelingfor Predictors
of Non-Q Wave MyocardialInfarction
Odds
Covariate Coefficient p Value Ratio 95%CI
Intercept -2.75
UseofDCA 0.71 0.010 2.0 1.19,3.48
Graftlesion 0.74 0.024 2.1 1.10,3.98
Unstableangina -0.61 0.032 0.5 0.31,0.95
Bolusandinfusion -0.52 0.045 0.6 0.36,0.98
c7E3





The followingvariableswere includedin a logisticregression
modelto determineindependentbaselinepatientand lesion
variablespredictiveof the developmentof non-Qwavemyo-
cardialinfarction:patientage, gender,diabetesmellitus,un-
stableangina,saphenousveingraft lesionlocation,interven-
tional device(directionalatherectomyor PTCA) and study
treatment.The use of directionalatherectomywas indepen-
dentlyassociatedwitha twofoldincreaseinriskofnon-Qwave
myocardialinfarction(p = 0.010).Saphenousveingraftlesions
were alsoindependentlyassociatedwith an increasedriskof
non-Q wave rnyocardialinfarction,whereastreatmentwith
bolus and infusionof c7E3 (p = 0.045)and a historyof
unstableangina(p = 0.032)wereassociatedwitha lowerrisk
of non-Qwavemyocardialinfarction.
Effectof c7E3on clinical outcomes(Table4). In patients
undergoingPTCA, c7E3 bolusand infusionwas associated
with a’41Y0reductionin the 30-daycompositeclinicalend
pointfrom 12.5%to 7.5%(p = 0.004).Thissametrend was
seenin the directionalatherectomygroup,witha correspond-
ing 60Y0reductionin the compositeclinicaloutcomefrom
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Figure2. Thirty-daynon-Q wave myocardial infarction rates in the
three treatment groups for patients undergoingPTCA (left) or direc-
tional atherectomy (right).Patients in the directional atherectomy
group who received placebo had an excess risk of non-Q wave
myocardialinfarction compared with patients in the PTCA groupwho
receivedplacebo.Bolusand infusionof c7E3abolishedthis excessrisk,
reducing the non-Q wave myocardial infarction rate in directional
atherectomy group to a level similar to that in the PTCA group.
three treatmentarmsin both PTCAand directionalatherec-
tomygroups.
The majoreffectof c7E3for both PTCAand directional
atherectomygroupswasin the reductionofmyocardialinfarc-
tion and need for repeatintervention.In patientsundergoing
PTCA,there was a significantreductionin the rate of total
myocardialinfarction,principallydueto a decreasein Q wave
myocardialinfarction(2.6%for theplacebogroupvs.0.8!Z0for
the bolusplus infusiongroup,p = 0.017).There was also a
trend towarda reductionin non-Qwavemyocardialinfarc-
tions,althoughthe magnitudeofbenefitwassmall(Fig.2). In
the directionalatherectomygroup,the rate of non-Qwave
myocardialinfarction for patients receivingplacebo was





BohIs+ p Value Bolus+ p Value
Bolus Infusion (placebovs. Bolus Infusion (placebovs.
Placebo c7E3 c7E3 bolus+ Placebo c7E3 c7E3 bolus+
(n= 606) (n= 609) (n= 603) infusion) (n= 65) (n= 65) (n= 67) infusion)
Death 11(1.8) 9 (1.5) 9 (1.5) 0.658 0 0 0
MI
Total 50(8.3) 35(5.8) 29(4.8) 0.018 10(15.4) 8 (12.3) 3 (4.5) 0.046
Q wave 16(2.6) 5 (0.8) 5 (0.8) 0.017 0 2(3.1) o
Non-Qwave 34(5.6) 31(5.1) 24(4.0) 0.191 10(15.4) 6(9.2) 3(4,5) 0.046
Urgentrepeatintervention 29(4.8) 21(3.6) 6(1.0) <0.001 2(3.1) 2(3.1) o 0.151
Emergencycoronarybypass 24(4.0) 14(2.3) 10(1.7) 0.016 14(1.5) 2(3,1) 2 (3.0) 0.582
Urgentstentplacement 4 (0.7) 9(1.5) 4(0.7) 0.994 0 3(4.6) o
Urgentintraaorticballoonpump 1(0.2) o 1(0.2) 0.997 0 0 0
Compositeofabove 76(12.5) 68(11.3) 45(7.5) 0.004 12(18.5) 9(13.8) 5 (7.5) 0.078
Dataexpressedare number(%)ofpatients.Abbreviationsas inTables1and3.
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Table5. BleedingComplicationsbyTreatmentGroupandInterventionalDeviceUsed
PTCA DCA
Bohrs+ p Value Bohrs+ pValue
Bohrs Infusion (placebovs. Bohrs Infusion (placebovs.
Placebo c7E3 c7E3 bohrs+ Placebo c7E3 c7E3 bolus+
(n= 606) (n= 609) (n= 603) infusion) (n= 65) (n= 65) (n= 67) infusion)




Total 21(3,5) 54(8.9) 64(10.6) <0.001 1(1.5) 5 (7.7) 7 (10.4) 0.06
Periaccessite 15(2.5) 41(6.7) 44(7.3) <0.001 1(1.5) 2 (3.1) 4(6.0) 0.37
Intracranial 1(0.2) 1(0.2) 2 (0.3) 0.64 0 0 0
Bloodtransfusion 44(7.3) 83(13.6) 89(14.8) <0.001 2(3.1) 7(10.8) 7 (10.4) 0.17
Minorbleeding 56(9.2) 93(15.3) 99(16.4) <0,001 8(12.3) 12(18.5) 17(25.4) 0.08
Datapresentedare number(%)ofpatients.Abbreviationsas in Tables1arr~3.
infusionin thoseundergoingdirectionalatherectomywasthe
decreasein non-Qwavemyocardialinfarctions(Fig.2). The
need for repeat urgent revascularizationaccountedfor the
remainderof the benefitof c7E3.
Bleedingcomplications(Table5), Majorcoronarybypass
surgery-and noncoronarybypass surgery-relatedbleeding
rateswere similarin the PTCAand directionalatherectomy
groups.The use of c7E3was associatedwith greater major
bleedingeventsthan placebouse for both PTCAand direc-
tional atherectomypatientgroups.Minorbleedingoccurred
more frequentlywith the use of directionalatherectomy
(13.6%for the PTCA group vs. 18.8%for the directional





for the PTCA and directionalatherectomygroups,analyzed




35%to 25%in the patientsundergoingPTCA(p < 0.001).In




effectweretoo smallto be statisticallymeaningful.
The medium-termoutcomeof patientswho experienced
non-Qwavemyocardialinfarctionafter the indexprocedure
wasalso determined.Ninety-ninepatientswere identifiedas
havinga periproceduralnon-Q wave myocardialinfarction,
irrespectiveof the intetventionaldeviceused. In all these
patientsnon-Qwavemyocardialinfarctionwas the first end
pointexperienced.Subsequentadverseclinicaleventsoccurred
in 38 (38Yo)of 99 patients in the following6 months.In
contrast,of the 1,842patientswho did not experienceany
adverseeventduringtheir indexhospitalperiod,372 (2090)
had an adverseeventin the following6 months(p K 0.001).
Themajorityof subsequenteventsin the non-Qwavemyocar-
dialinfarctiongroup(30[79%]of 38)occurredwithin30days
of the indexprocedure,whereasfor patientswhowere event
free at discharge,the majorityof subsequentadverseevents
(333[90%]of 372)occurredbetween30 daysand 6 months.
Discussion
Patientswho underwentdirectionalatherectomyin the





Bolus Infusion p Value Bolus Infusion p Value
Placebo c7E3 C7E3 (placebovs. Placebo c7E3 c7E3 (placebovs.
(n = 606) (n= 609) (n= 603) bohrs+ infusion) (n= 65) (n = 65) (n= 67) bohrs+ infusion)
Death 20(3.4) 17(2.8) 18(3.0) 0.751 1(1.6) 1(1.5) 1(1.5) 0.964
MI(all) 58(9.6) 47(7.8) 40(6.7) 0.062 11(17.1) 8 (12.3) 3 (4.5) 0.025
Repeatpercutaneousintervention 127(21.6) 121(20.5) 84(14.4) 0.001 9(14.0) 9 (13.9) 10(15.1) 0.931
Coronarybypasssurgery 62(10.5) 54(9.2) 43(7.3) 0.05 6(9.8) 8 (12.6) 9 (13.6) 0.447
Compositeofabove 207(34.6) 198(32.9) 149(25.1) <0.001 23(35.7) 19(29.2) 21(31.7) 0.519
Datapresentedare number(%)ofpatients.Abbreviationsas in Tables1and3.
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12-hinfusionof the glycoproteinIIb/IIIa receptor inhibitor
c7E3reducedthisexcessrisk.In contrast,patientswhounder-
wentPTCAhad a muchlowerrate of non-Qwavemyocardial
infarction,andthecorrespondingeffectofc7E3onthisadverse
outcomewas lessmarked.There wasno incrementalriskof
majorbleedingwhen directionalatherectomywas combined
withglycoproteinIIbiIIIareceptorinhibition,althoughdirec-





the EPIC trial providesindependentconfirmationof the
increasedriskof non-Qwavemyocardialinfarctionassociated
withthisprocedure.Thisrate isremarkablysimilarto the 1970




significantin that the EPICtrialwasnot specificallydesigned
to evaluatethe techniqueof directionalatherectomy.





noneof thosestudieshad an independentblinded,reviewof
adverseeventsbyan eventscommittee.DatafromCAVEAT-I
clearlyshowedthat relianceon individualsite reportingof
non-Qwavemyocardialinfarctioncan resultin an underesti-
mationof the true incidenceof this complication(l). These
findingsunderscore the importance of independent and
blindedadjudicationof studyend pointsin largemulticenter
trials.
Platelet dependencyof non-Qwavemyocardialinfarction
after directionalatherectomy.The reductionin non-Qwave
myocardialinfarctionafterdirectionalatherectomywithglyco-
protein IIb/IIIa receptorinhibitionsuggeststhat plateletag-
gregationand thrombusformationare integralcomponentsof
thiscomplication.Alternativemechanismsrelatedto thebulky
sizeof the atherectomycatheterand its potentialfor plaque
embolizationhavebeen previouslysuggested(10,17)but not
confirmedin the clinicalsituation.Althoughspeculative,it is
plausiblethatdirectionalatherectomyleadsto markedplatelet
aggregationbecauseof its attendantexposureof atheroscle-
roticvesselwallcomponents(media,collagen-I,tissuefactor
and lipid-richcore). These components,togetherwith any
associated mural thrombus, are all highly thrombogenic
(18,19).Alternatively,the atherectomycatheteritselfor the
deeper arterial injurythat can resultmay inducehigh local
shearratesthatpredisposeto plateletthrombiformation(20).
Althoughthe potentialmechanismsrequirefurtherinvestiga-
tion, the identificationof a platelet aggregation-mediated
effecthasprovidedaviablemeansofminimizingthe important
potentialrisksassociatedwithdirectionalatherectomy.
Clinical significanceof CK elevations. Despitethe excess
of non-Qwavemyocardialinfarctionsin patientsundergoing
directionalatherectomy,a numberof investigatorshaveques-
tioned whether isolatedmoderate increases(less than five
timesnormal)have any clinicalinfluenceon long-termout-
come(21–23).Yet, in CAVEAT-I,a definiteand incremental
relationbetweenCK-MBlevelsand adverseclinicaloutcomes
was found (24). The apparent importanceof small infarcts
aftercorona~ interventionon long-termclinicaloutcomehas
nowbeen highlightedby severalinvestigators(25-27)and is
supportedby the results of the present study. Of the 99
patientswho had elevatedCK-MBlevelsresultingfrom the
procedure,38(38%)hada furtheradverseeventintheensuing
6 months, almost twice the rate of patients who had an
uncomplicatedhospitalcourse.Overall,thesefindingsuggest
thatCKelevationsmaybeharbingersoffurtheradverseevents
and shouldnot be dismissedas clinicallyinconsequential.
Becausethe outcomesafternon-Qwavemyocardialinfarc-








Studylimitations. 1) The presentstudyrepresentsa post
hoc analysisof a trial not specificallydesignedto compare
PTCA with directionalatherectomy.2) Patients were not
randomizedto undergoPTCAor directionalatherectomy,and
patientselectionbiasesmayhavebeen introduced.Thisbias
was in fact evidentin the differencesin demographic,lesion
andproceduralprofilesin the twogroups.However,although
thesedifferenceswerepresent,theycharacterizedthe patients
imdergoingdirectionalatherectomyas a group expectedto
have a considerablylower rather than higher risk of acute
complications.The findingthat directionalatherectomywas
associatedwitha greaterincidenceof non-Qwavemyocardial
infarctionis actuallystrengthenedby these differences.3)
Althoughthis study suggeststhat non-Q wave myocardial
infarctionafterdirectionalatherectomyis plateletdependent,
it doesnotprovidea directmeasureofplateletinvolvementin
the processof directionalatherectomy-relatednon-Q wave
myocardialinfarction.4) The monoclinal antibodyc7E3
standsout amongthe glycoproteinIIb/IIIareceptorinhibitors
asbeingrelativelyintegrin“nonspecific,”interactingwithother
integrins,includingthe vitronectinreceptor, @3 (28) and
Mac-1integrin(29,30).We cannotexcludethe effectof c7E3
on other integrinsas a contributoryfactorto our findings.5)
Although the present study represents the largest clinical
experienceof glycoproteinIIb/IIIareceptorinhibitionduring
directionalatherectomy,the numberof patients involvedis
relativelysmall,and the resultsmaybe subjectto typeI error.
However,as a subgroupanalysis,this studywas intendedto
explorea hypothesis,not providedefinitiveproof.As such,it
has providedinitialevidenceof the keyrole of plateletsand
JACC Vol. 28, No. 4 LEFKOVITS ET AL
October 1996:849-55
855






1. TopolEJ, Leya F, PinkertonCA, et al. A comparisonof directional
atherectomywith coronaryangioplastyin patientswith coronaryartery
disease.N EnglJ Med1993;329:221-7.
2. HolmesDR,TopolEJ, CaliffRM,et al.A multicenterandomizedtrirdof
coronaryangioplastyversusdirectionalatherectomyforpatientswithsaphe-
nousveinbypassgraftlesions.Circulation1995;91:1966-74.






5. TopolEJ, CaliffRM,WeismanHF, et al. Randomizedtrial of coronary
interventionwithantibodyagainstplateletIIb/IIIaintegrirrforreductionof
clinicalrestenosis:resultsat sixmonths.Lancet1994;343:881–6.
6. EllisSG,VandormaelMG,CowleyMJ,et al. Coronarymorphologicand
clinicaldeterminantsofproceduraloutcomewithangioplastyformultivessel
coronarydisease.Circulation1990;82:1193-202.





8. LeonMB,KuntzRE, PopmaJJ, et al. Acuteangiographic,intravascular
ultrasoundand clinicalresultsof directionalatherectomyin the Optimal
AtherectomyRestenosisStudy[abstract].J AmCoilCardiol1995;S25:137A.
9. BairnDS,KuntzRE, SharmaSK,et al. Acuteresultsof the randomized
phaseof theBalloonversusOptimalAtherectomyTrial(BOAT)[abstract].
Circulation1995;92Suppl1:1-544.




of primaryatheromatousand restenosislesionsin coronaryarteriesand
saphenousveingrafts.AmJ Cardiol1992;70:449-54.
12.FishmanR, KuntzR, CarrozzaJr J, et al.Long-termresultsof directional
coronaryatherectomy:predictorsofrestenosis.J AmCoilCardiol1992;20:
1101-10.

















directional coronazy atherectomy. J Am COOCardi;l 1992;19:1372-9.
HinoharaT,RoweMH,RobertsonGC,et al.Effectoflesioncharacteristics
on outcomeof directionalcoronaryatherectomy,J Am Co]]Cardiol
1991;17:1112-20.
CarrozzaJ, BairnD. Complicationsof directionalcoronaryatherectomy:
incidence,causes,andmanagement.AmJ Cardiol1993;72:47E-54E.
Femandez-OrtirA, BadimonJJ, Falk E, et al. Characterizationof the
relativethrombogenicityofatheroscleroticplaquecomponents:implications
forplaquempture.J AmCOOCardiol1994;23:1562-9.
BadimonL, BadimonJJ, TurittoVT,VallabhajosulaS,FusterV. Platelet
thrombusformationon collagentypeL A modelof deep vesselinjury.
Influenceofbloodrheology,vonWillebrandfactor,andbloodcoagulation.
Circulation1988;78:1431-42.
MailhacA, BadimonJJ, FallenJT, et al. Effectof an eccentricsevere
stenosison fibrinogen)depositionon severelydamagedvesselwall in
mterial thrombosis.Relativecontributionof fibrinogen)and platelets.
Circulation1994;90:988-96.
KugelmassAD, CohenDJ, MoscucciM, et al. Elevationof the creatine
kinasemyocardialisoformfollowingotherwisesuccessfuldirectionalcoro-
naryatherectomyandstenting.AmJ Cardiol1994;74:748-54.
Oh JK, ShubC, IlstrupDM, ReederGS. Creatinekinasereleaseafter
successfulpercutaneoustransluminalcoronaryangioplasty.Am Heart J
1985;109:1225-31.
Klein LW, Kramer BL, HowardE, Lesch M. Incidenceand clinical













27.TardiffBE, GrangerCB, WoodliefL, et al. Prognosticsignificanceof
postinterventionisozymeelevations[abstract].Circulation1995;92Suppl
1:1-544.
28. Charo IF, BekeartLS, PhillipsDR. Platelet glycoproteirrIIb-IIIa-like
proteinsmediateendothelialcellattachmento adhesiveproteinsand the
extracelhdarmatrix.J BiolChem1987;262:9935-8.
29.AltieriDC,BaderR, MannucciPM,EdgingtonTS.Oligospecificityof the
cellularadhesionreceptorMac-1encompassesan induciblerecognition
specificityforfibrinogen.J CellBiol1988;107:1893–900.
30.ZhouL,LeeDH,PlesciaJ, LarrCY,AltieriDC.Differentialligandbinding
specificitiesof recombinantCDllb/CD18integrinI-domain.J BiolChem
1994;269:17075-9.
